Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CVM NASDAQ:GOVX NASDAQ:MBIO NASDAQ:PRFX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCEL-SCI$3.96-5.0%$3.27$1.98▼$66.60$21.07M0.3205,954 shs417,623 shsGOVXGeoVax Labs$0.76+4.0%$0.91$0.43▼$11.18$12.18M3.362.67 million shs983,499 shsMBIOMustang Bio$2.18-6.0%$1.48$0.89▼$24.00$9.54M2.161.63 million shs373,533 shsPRFXPainReform$1.45-2.7%$1.72$1.25▼$16.63$2.92M0.561.47 million shs148,060 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCEL-SCI-5.04%+12.18%+72.93%-48.19%-90.70%GOVXGeoVax Labs+4.02%+12.48%-17.81%-8.38%-74.83%MBIOMustang Bio-6.03%-17.74%+103.74%+63.91%-88.12%PRFXPainReform-2.68%+4.32%-14.71%-29.27%-35.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVMCEL-SCI0.1215 of 5 stars0.02.00.00.00.60.00.6GOVXGeoVax Labs2.2302 of 5 stars3.62.00.00.03.00.00.6MBIOMustang Bio0.7151 of 5 stars0.05.00.00.01.10.00.6PRFXPainReform0.5085 of 5 stars0.02.00.00.01.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVMCEL-SCI 0.00N/AN/AN/AGOVXGeoVax Labs 3.20Buy$8.881,067.76% UpsideMBIOMustang Bio 0.00N/AN/AN/APRFXPainReform 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest PRFX, CVM, GOVX, and MBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/16/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/2/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $9.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AGOVXGeoVax Labs$3.95M3.07N/AN/A$0.48 per share1.58MBIOMustang BioN/AN/AN/AN/A($2.11) per shareN/APRFXPainReformN/AN/AN/AN/A$2.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/AGOVXGeoVax Labs-$24.99M-$3.65N/AN/AN/A-438.20%-511.96%-286.58%8/5/2025 (Estimated)MBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)PRFXPainReform-$14.59M-$147.33N/A∞N/AN/AN/AN/A8/21/2025 (Estimated)Latest PRFX, CVM, GOVX, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025GOVXGeoVax Labs-$0.41N/AN/AN/A$0.37 millionN/A5/14/2025Q1 2025MBIOMustang BioN/A-$0.05N/A-$0.05N/AN/A5/1/2025Q1 2025GOVXGeoVax Labs-$0.59-$0.45+$0.14-$0.45$0.75 million$1.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVMCEL-SCIN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVMCEL-SCI0.661.071.09GOVXGeoVax LabsN/A3.623.62MBIOMustang BioN/A1.341.34PRFXPainReformN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVMCEL-SCI12.08%GOVXGeoVax Labs6.09%MBIOMustang Bio9.95%PRFXPainReform37.28%Insider OwnershipCompanyInsider OwnershipCVMCEL-SCI9.93%GOVXGeoVax Labs1.20%MBIOMustang Bio0.21%PRFXPainReform34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVMCEL-SCI435.32 million64.67 millionOptionableGOVXGeoVax Labs1015.93 million15.73 millionNot OptionableMBIOMustang Bio1004.38 million4.37 millionNot OptionablePRFXPainReform42.01 million1.32 millionNot OptionablePRFX, CVM, GOVX, and MBIO HeadlinesRecent News About These CompaniesPainreform stock falls after announcing strategic investment in ...July 11, 2025 | investing.comPainReform invests in LayerBio to expand into ophthalmologyJuly 11, 2025 | investing.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand ...July 11, 2025 | seekingalpha.comPainreform stock falls after announcing strategic investment in LayerBioJuly 10, 2025 | au.investing.comPainreform Shares Drop 11% After Revealing Strategic Stake in LayerBioJuly 10, 2025 | msn.comPainReform Expands into Ophthalmology with Strategic Investment in LayerBioJuly 10, 2025 | tipranks.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain ...July 10, 2025 | gurufocus.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain ...July 10, 2025 | gurufocus.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBioJuly 10, 2025 | globenewswire.comBlade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software SalesMay 27, 2025 | prnewswire.comPainReform Ltd.May 12, 2025 | barrons.comPainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania’s Largest Solar ProjectsMay 7, 2025 | finance.yahoo.comPainReform Ltd. Launches Strategic Pilot Program with Econergy Renewable Energy Ltd. to Optimize Solar Energy Production using DeepSolar™ PlatformMay 7, 2025 | quiverquant.comQPainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar ProjectsMay 7, 2025 | globenewswire.comPainReform Regains Nasdaq Compliance as of April 16, 2025April 17, 2025 | tipranks.comPainReform announces expansion into SEM sectorApril 10, 2025 | markets.businessinsider.comPainReform Shareholders Approve Key Proposals at April MeetingApril 10, 2025 | tipranks.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar’s AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | finance.yahoo.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | globenewswire.comPainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization MarketApril 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRFX, CVM, GOVX, and MBIO Company DescriptionsCEL-SCI NYSE:CVM$3.96 -0.21 (-5.04%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.97 +0.01 (+0.25%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.GeoVax Labs NASDAQ:GOVX$0.76 +0.03 (+4.02%) As of 07/18/2025 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Mustang Bio NASDAQ:MBIO$2.18 -0.14 (-6.03%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.19 +0.01 (+0.69%) As of 07/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.PainReform NASDAQ:PRFX$1.45 -0.04 (-2.68%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.44 -0.01 (-0.69%) As of 07/18/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
